Vasarya Therapeutics, Inc.
Publicly observedCamden, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Camden | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Vasarya Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | PFB5FMPM2666 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2024Publicly observed
NIH SBIR/STTR award: Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis
USD 1,126,840.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2024Publicly observed
NIH SBIR/STTR award: Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis
USD 1,107,500.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.